ORMP Oramed Pharmaceuticals Inc.
-
Oramed Pharmaceuticals Missed Consensus Estimates
Monday, August 10, 2026 · 12:00 AM ET
Oramed Pharmaceuticals (ORMP) reported a loss of $0.09 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus earnings estimate was $0.43 per share. The company missed consensus estimates by 120.93%.
Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered in Jerusalem, Israel.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.09)
Earnings Whisper®
—
Consensus Estimate
$0.43
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—